Prioritizing health-care funding

Internal Medicine Journal

Volumn 35, Issue 7, 2005, Pages 409-412

  O'Donnell, John L ^a,b   Smyth, D ^a   Frampton, C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Empiricism; Funding criteria; Health care strategies; Rationalism; Rationing

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT;

ARTHRITIS; BREAST CANCER; CANCER SCREENING; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH PROGRAM; PHILOSOPHY; POLITICS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION; REVIEW; RISK BENEFIT ANALYSIS; THEORY; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; COST ALLOCATION; DRUG COSTS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE RATIONING; HEALTH EXPENDITURES; HEALTH PRIORITIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEW ZEALAND; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21444436333     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.00839.x     Document Type: Review

References (16)

1. Vandenbroucke JP. Clinical investigation in the 20th century: the ascendancy of numerical reasoning. Lancet 1998; 352 Suppl: S1112-16.
2. Vandenbroucke JP. 175th anniversary lecture. Medical journals and the shaping of medical knowledge. Lancet 1998; 352: 2001-6.
3. Tanenbaum SJ. Knowing and acting in medical practice: the epistemological politics of outcomes research. In: Nelson JL, Nelson HL, eds. Meaning and Medicine: A Reader on the Philosophy of Health Care. New York: Routledge; 1999: 61-72.
4. Pharmac. Pharmaceutical Management Agency Annual Review 2003: Pharmac 10 years on. Available from URL http:// www.pharmac.govt.nz
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multi-centre trial. Lancet 2002; 359: 1187-93.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7-22.
8. Raffle AE, Alden B, Quinn M, Babb PJ, Brett MT. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ 2003; 326: 901-04.
9. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE et al. Long-term effects of mamography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-19.
10. Davidoff F. Standing statistics right side up. Ann Intern Med 1999; 130: 1019-21.
11. Goodman SN. Towards evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999; 130: 995-1004.
12. Neyman J, Pearson E. On the problem of the most efficient tests of statistical hypotheses. Philos Trans R Soc London Ser A 1933; 231: 289-337.
13. Good PI, Hardin JW, eds. Common Errors in Statistics (and How to Avoid Them). Hoboken: John Wiley & Sons Inc.; 2003.
14. Goodman S. P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate. Am J Epidemiol 1993; 137: 485-95.
15. Piattelli-Palmarini M. Inevitable Illusions: How Mistakes of Reason Rule Our Minds. New York: John Wiley & Son Inc.; 1994.
16. Plsek PE, Greenhalgh T. The challenge of complexity in health care. BMJ 2001; 323: 625-8.